FY2025 EPS Estimates for Vericel Decreased by Analyst

Vericel Corporation (NASDAQ:VCEL) – Leerink Partnrs lowered their FY2025 earnings per share estimates for Vericel in a research note issued on Thursday, July 31st. Leerink Partnrs analyst M. Kratky now expects that the biotechnology company will post earnings per share of $0.23 for the year, down from their prior estimate of $0.33. The consensus estimate for Vericel’s current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for Vericel’s FY2026 earnings at $0.67 EPS, FY2027 earnings at $1.20 EPS and FY2028 earnings at $1.86 EPS.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. The business had revenue of $63.24 million during the quarter, compared to the consensus estimate of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.10) earnings per share.

A number of other brokerages also recently commented on VCEL. Wall Street Zen downgraded Vericel from a “hold” rating to a “sell” rating in a research note on Monday, May 12th. Canaccord Genuity Group decreased their target price on Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday. Stephens restated an “overweight” rating and issued a $67.00 target price on shares of Vericel in a research note on Monday, June 16th. Finally, Truist Financial decreased their target price on Vericel from $61.00 to $51.00 and set a “buy” rating for the company in a research note on Friday, April 11th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and an average price target of $59.86.

Vericel Stock Performance

NASDAQ:VCEL opened at $35.63 on Monday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of 296.94 and a beta of 1.27. Vericel has a one year low of $33.09 and a one year high of $63.00. The stock has a 50-day simple moving average of $40.83 and a 200 day simple moving average of $45.40.

Institutional Investors Weigh In On Vericel

A number of hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors lifted its position in Vericel by 3.4% in the fourth quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company’s stock worth $336,000 after purchasing an additional 199 shares during the period. State of Wyoming lifted its position in Vericel by 3.8% in the first quarter. State of Wyoming now owns 10,428 shares of the biotechnology company’s stock worth $465,000 after purchasing an additional 381 shares during the period. Summit Investment Advisors Inc. lifted its position in Vericel by 8.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,137 shares of the biotechnology company’s stock worth $282,000 after purchasing an additional 405 shares during the period. Maryland State Retirement & Pension System lifted its position in Vericel by 2.8% in the second quarter. Maryland State Retirement & Pension System now owns 14,795 shares of the biotechnology company’s stock worth $630,000 after purchasing an additional 408 shares during the period. Finally, Oppenheimer Asset Management Inc. lifted its position in Vericel by 2.6% in the second quarter. Oppenheimer Asset Management Inc. now owns 20,092 shares of the biotechnology company’s stock worth $855,000 after purchasing an additional 516 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.